Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide H3K4me3 after MK2206/DMSO treatment of T47D cells

ABSTRACT: We perfomed ChIP-seq using H3K4me3 antibodies in T47D cells after 24 hour treatment with the AKT inhibitor MK2206 or DMSO. We demonstrate that at a selected group of loci H3K4me3 is affected by AKT inhibition.

ORGANISM(S): Homo sapiens

PROVIDER: GSE80592 | GEO | 2016/06/14

SECONDARY ACCESSION(S): PRJNA319401

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genome-wide H3K4me3 after MK2206/DMSO treatment of T47D cells

Project description:We perfomed ChIP-seq using H3K4me3 antibodies in T47D cells after 24 hour treatment with the AKT inhibitor MK2206 or DMSO. We demonstrate that at a selected group of loci H3K4me3 is affected by AKT inhibition. Comparison of genome-wide H3K4me3 binding after AKT inhibition vs vehicle

2016-06-14 | E-GEOD-80592 | biostudies-arrayexpress

Genome-wide KDM5A occupancy after MK2206/DMSO treatment of T47D cells

Project description:We perfomed ChIP-seq using KDM5A antibodies in T47D cells after 24 hour treatment with the AKT inhibitor MK2206 or DMSO. We show that the cistrome of the H3K4 demethylase KDM5A is affected by AKT inhibition.

2016-06-14 | GSE80593 | GEO

Genome-wide KDM5A occupancy after MK2206/DMSO treatment of T47D cells

2016-06-14 | E-GEOD-80593 | biostudies-arrayexpress

Messenger RNA expression after MK2206/DMSO treatment of T47D cells

Project description:We performed RNA-seq in T47D cells after 24 hour treatment with the AKT inhibitor MK2206 or DMSO. We show that a group of transcripts is differentailly expressed after AKT inhibition.

2016-06-14 | GSE80591 | GEO

Messenger RNA expression after MK2206/DMSO treatment of T47D cells

2016-06-14 | E-GEOD-80591 | biostudies-arrayexpress

RNA-seq analysis of AKTi MK2206 resistant BT474 and T47D cells

Project description:RNA-seq analysis of AKTi MK2206 resistant BT474 and T47D cells

| PRJNA484709 | ENA

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Project description:This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with relapsed lymphoma. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

| 2099453 | ecrin-mdr-crc

Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Project description:This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with advanced gastric or gastroesophageal junction cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

| 2099584 | ecrin-mdr-crc

Akt inhibitor MK2206 prevents influenza A(H1N1)pdm09 virus infection in vitro

Project description:The influenza A(H1N1)pdm09 virus caused a global flu pandemic in 2009 and contributes to seasonal epidemics. Different treatment and prevention options for influenza have been developed and applied with limited success. Here we report that an Akt inhibitor MK2206 possesses potent antiviral activity against influenza A(H1N1)pdm09 virus in vitro. We showed that MK2206 blocks the entry of different A(H1N1)pdm09 strains into cells. Moreover, MK2206 prevented A(H1N1)pdm09-mediated activation of cellular signaling pathways and the development of cellular immune responses. Importantly, A(H1N1)pdm09 virus was unable to develop resistance to MK2206. Thus, MK2206 is a potent anti-influenza A(H1N1)pdm09 agent.

2014-01-23 | GSE54293 | GEO

Akt inhibitor MK2206 prevents influenza A(H1N1)pdm09 virus infection in vitro

2014-01-23 | E-GEOD-54293 | biostudies-arrayexpress